Novation Signs Agreement for Kimberly-Clark's InteguSeal Microbial Sealant

 

June 30, 2008

June 30, 2008 - Kimberly-Clark Health Care said today it received an agreement from Novation to offer its alliance members the InteguSeal Microbial Sealant.

As part of Novation's New Technology Program, the agreement was awarded to the global healthcare business of Kimberly-Clark Corp. after Novation and its Clinical Council determined InteguSeal Microbial Sealant offers incremental benefit to patient care and patient safety.

Kimberly-Clark said surgical site infections can significantly impact clinical and financial outcomes at a hospital. Compared with uninfected patients, those with a surgical site infection may remain in hospitals seven days longer, have a 60 percent increased probability of admittance to intensive care units and are five times more likely to return for continued care within 30 days of discharge.

InteguSeal is designed to reduce the risk of skin flora contamination during a surgical procedure by sealing and immobilizing pathogens to help protect against migration of skin flora into an incision. InteguSeal Microbial Sealant received FDA clearance as a class II medical device in 2006.

For more information: www.Novationco.com, www.kchealthcare.com